---
schema_version: "secwatch.filing_event.v1"
accession: "0001802768-23-000013"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:45:13.847610+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma Q1 adjusted cash receipts $1,131M (+87% YoY); reaffirms FY guidance $2,850-2,950M

## Summary
- Adjusted Cash Receipts $1,131M, +87% YoY; underlying growth 11% ex-Zavzpret milestone and Biohaven payments.
- GAAP net cash from ops $1,034M (+125% YoY) includes $475M Zavzpret milestone and $35M Airsupra payment.
- Announced up to $1.6B in new royalty deals (Spinraza, pelacarsen, KarXT) and $1.0B share buyback program.
- Reaffirmed FY23 Adjusted Cash Receipts guidance $2,850-2,950M (underlying growth 4-9% ex-milestones).
- Portfolio milestones: FDA approvals for Zavzpret, Airsupra, Trodelvy; positive Xtandi Phase 3 data.

## SEC filing metadata
- accession: 0001802768-23-000013
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000180276823000013/0001802768-23-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000180276823000013/rprx-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001802768-23-000013
- JSON: https://secwatch.observer/filing/0001802768-23-000013.json
- Plain text: https://secwatch.observer/filing/0001802768-23-000013.txt

## Key facts
- Earnings Releases
  Royalty Pharma plc updated its the quarter ended March 31, 2023 guidance (reaffirmed).
  - Period: the quarter ended March 31, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On May 9, 2023, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended March 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000180276823000013/0001802768-23-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.